Jiangsu GDK Biotechnology Co Ltd Market Cap ($231.66 Million)
Market Cap & Net Worth: Jiangsu GDK Biotechnology Co Ltd (688670)
Jiangsu GDK Biotechnology Co Ltd market cap. Jiangsu GDK Biotechnology Co Ltd (SHG:688670) has a market capitalization of $231.66 Million (CN¥1.58 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #15718 globally and #4576 in its home market, demonstrating a 3.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu GDK Biotechnology Co Ltd's stock price CN¥12.85 by its total outstanding shares 123200000 (123.20 Million). Also see Jiangsu GDK Biotechnology Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Jiangsu GDK Biotechnology Co Ltd Market Cap History (2021–2026)
Jiangsu GDK Biotechnology Co Ltd market cap history from 2021 to 2026. Data shows change from $952.52 Million to $231.66 Million (-24.86% CAGR). Check Jiangsu GDK Biotechnology Co Ltd stock quote for real-time trading data and today's change.
Jiangsu GDK Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu GDK Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Jiangsu GDK Biotechnology Co Ltd (688670) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.22x
Jiangsu GDK Biotechnology Co Ltd's market cap is 3.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $952.52 Million | $392.27 Million | $82.46 Million | 2.43x | 11.55x |
| 2022 | $551.32 Million | $318.49 Million | $41.54 Million | 1.73x | 13.27x |
| 2023 | $513.08 Million | $134.59 Million | -$70.99 Million | 3.81x | N/A |
| 2024 | $218.50 Million | $80.80 Million | -$93.50 Million | 2.70x | N/A |
| 2025 | $364.71 Million | $113.23 Million | -$173.47 Million | 3.22x | N/A |
Competitor Companies of 688670 by Market Capitalization
Companies near Jiangsu GDK Biotechnology Co Ltd in the global market cap rankings as of November 8, 2026. Also see total assets of Jiangsu GDK Biotechnology Co Ltd for a full breakdown of the balance sheet.
Key companies related to Jiangsu GDK Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Jiangsu GDK Biotechnology Co Ltd (2021–2026)
Market capitalization of Jiangsu GDK Biotechnology Co Ltd from 2021 to today. Between 2021 and today, Jiangsu GDK Biotechnology Co Ltd's market cap moved from $952.52 Million to $ 231.66 Million, with a yearly change of -24.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥231.66 Million | -36.48% |
| 2025 | CN¥364.71 Million | +66.91% |
| 2024 | CN¥218.50 Million | -57.41% |
| 2023 | CN¥513.08 Million | -6.94% |
| 2022 | CN¥551.32 Million | -42.12% |
| 2021 | CN¥952.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Jiangsu GDK Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $231.66 Million USD |
| MoneyControl | $231.66 Million USD |
| MarketWatch | $231.66 Million USD |
| marketcap.company | $231.66 Million USD |
| Reuters | $231.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more